


FORM PTO-1390 (REV. 10-2003)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 1718-0218PUS1
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>107519332</b>
INTERNATIONAL APPLICATION NO. PCT/SE2003/001100	INTERNATIONAL FILING DATE June 24, 2003	PRIORITY DATE CLAIMED June 27, 2002		
TITLE OF INVENTION Synergistic Interaction of Abacavir and Alovudine				
APPLICANT(S) FOR DO/EO/US Goran MARDH				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))           <ul style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto (required only if not transmitted by the International Bureau). WO/2004/002433 A12</li> <li>b. <input type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ul> </p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).           <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4)</li> </ul> </p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).           <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ul> </p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).           <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been submitted to the Internal Bureau (See Box VIII-4-1 of the Request (PCT/R0/101), <b>copy attached</b>). The Power of Attorney or Authorization of Agent and Certificate under 37 CFR 3.73(b) Showing Chain of Title are: <input type="checkbox"/> attached hereto. <input type="checkbox"/> will follow.</li> </ul> </p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>				
Items 11. to 20. below concern document(s) or information included:				
<p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98, Form PTO-1449(s), and International Search Report (PCT/ISA/210) with 0 cited document(s).</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A preliminary amendment.</p> <p>14. <input checked="" type="checkbox"/> An Application Data Sheet</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: Express Mailing Certificate (Label No. EV 592977178 US) Formal Drawings - Three (3)</p>				

U.S. APPLICATION NO (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO		ATTORNEY'S DOCKET NUMBER		
<b>107519332</b>		PCT/SE2003/001100		1718-0218PUS1		
21. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY		
<b>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO Basic National Stage Fee ..... \$300.00 National Stage Search Fee ..... \$500.00 National Stage Examination Fee ..... \$200.00 <b>\$1000.00</b>						
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$950.00</b> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO. .... <b>\$790.00</b> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4). .... <b>\$750.00</b> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4). .... <b>\$100.00</b>						
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>		<b>\$ 1000.00</b>				
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)). <b>SHEETS OF SPEC &amp; DWG</b> 14 -100 = 0      0 x 250 =      \$0      \$ 0.00				<b>\$ 130.00</b>		
<b>CLAIMS</b> Total Claims      12 - 20 =      0      x \$50.00      \$ 0.00 Independent Claims      3 - 3 =      0      x \$200.00      \$ 0.00						
<b>MULTIPLE DEPENDENT CLAIM(S) (if applicable)</b> <b>TOTAL OF ABOVE CALCULATIONS =</b> <b>\$ 1130.00</b>						
<input type="checkbox"/> Applicant claims small entity status. See 37 C.F.R. § 1.27. The fees indicated above are reduced by 1/2. <b>SUBTOTAL =</b> <b>\$ 1130.00</b>						
Processing fee of <b>\$130.00</b> for furnishing the English translation later than 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(f)). <b>TOTAL NATIONAL FEE =</b> <b>\$</b>						
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property <b>TOTAL FEES ENCLOSED =</b> <b>\$ 1130.00</b>						
				<b>Amount to be: refunded</b> <b>\$</b> <b>charged</b> <b>\$</b>		
a. <input type="checkbox"/> A check in the amount of <b>\$0.00</b> to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account. No. 02-2448 in the amount of <b>\$1,130.00</b> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment to Deposit Account No. 02-2448.						
<b>NOTE: Where an appropriate time limit under 37 C.F.R. § 1.495 has not been met, a petition to revive (37 C.F.R. § 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>						
Send all correspondence to: <b>Birch, Stewart, Kolasch &amp; Birch, LLP or Customer No. 02292</b> <b>P.O. Box 747</b> <b>Falls Church, VA 22040-0747</b> <b>(703) 205-8000</b>						
Date: <u>December 23, 2004</u>						
 By <u>Leonard R. Svensson</u> , #30,330 /sbp						

10/519332  
DT09 Rec'd PCT/PTO 23 DEC 2004

MS PCT  
PATENT  
1718-0218PUS1

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Goran MARDH Conf.:

Appl. No.: NEW Group:

Filed: December 23, 2004 Examiner: UNASSIGNED

For: SYNERGISTIC INTERACTION OF AVACAVIR AND  
ALOVUDINE

EXPRESS MAIL CERTIFICATE

**DATE DEPOSITED:** December 23, 2004

I hereby certify that the enclosed TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING ORDER UNDER 35 U.S.C. 371 AND RELATED DOCUMENTS is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Express Mail Label No.: EV 592977178 US

Date: December 23, 2004



Sandra B. Paulo

Mailing Address:

BIRCH, STEWART, KOLASCH & BIRCH, LLP  
P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000